Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mericitabine (R-7128) 是一种核苷HCV NS5B 聚合酶抑制剂。它充当 RNA 链终止子并防止 RNA 转录物在复制过程中延伸。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 767 | 现货 | ||
5 mg | ¥ 1,870 | 现货 | ||
10 mg | ¥ 2,550 | 现货 | ||
25 mg | ¥ 4,290 | 现货 | ||
50 mg | ¥ 6,130 | 现货 | ||
100 mg | ¥ 8,460 | 现货 | ||
500 mg | ¥ 16,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,980 | 现货 |
产品描述 | Mericitabine (R-7128) is a nucleoside HCV NS5B polymerase inhibitor. It acts as an RNA chain terminator and prevents the elongation of RNA transcripts during replication. |
体外活性 | PSI-6130 is converted through phosphorylation by cellular kinases to an active 5′-triphosphate metabolite, which inhibits the NS5B RNA polymerase of HCV. Mericitabine is an oral cytidine nucleoside analog prodrug that exhibits strong antiviral effectiveness against the HCV polymerase across all HCV genotypes. Mericitabine is a first-in-class nucleoside polymerase inhibitor (NPI), which requires intracellular uptake and phosphorylation to two active triphosphates. Mericitabine, a cytidine analogue, is an oral prodrug of PSI-6130. PSI-6130 has an EC90 value of 4.6±2 μM in the HCV replicon assay. Mericitabine displays high specificity for HCV, minimal cytotoxicity, and does not affect mitochondrial DNA. Mericitabine shows a relatively good safety profile and significant potency against HCV-1 [2][3]. |
别名 | R-7128, RG 7128, PSI 6130 diisobutyrate |
分子量 | 399.41 |
分子式 | C18H26FN3O6 |
CAS No. | 940908-79-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (250.37 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5037 mL | 12.5185 mL | 25.0369 mL | 62.5923 mL |
5 mM | 0.5007 mL | 2.5037 mL | 5.0074 mL | 12.5185 mL | |
10 mM | 0.2504 mL | 1.2518 mL | 2.5037 mL | 6.2592 mL | |
20 mM | 0.1252 mL | 0.6259 mL | 1.2518 mL | 3.1296 mL | |
50 mM | 0.0501 mL | 0.2504 mL | 0.5007 mL | 1.2518 mL | |
100 mM | 0.025 mL | 0.1252 mL | 0.2504 mL | 0.6259 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Mericitabine 940908-79-2 Microbiology/Virology Proteases/Proteasome HCV Protease R 7128 R7128 inhibit PSI 6130 R-7128 RG7128 PSI6130 RG 7128 PSI-6130 Diisobutyrate HCV Inhibitor PSI 6130 Diisobutyrate RG-7128 PSI-6130 PSI6130 Diisobutyrate Hepatitis C virus PSI 6130 diisobutyrate inhibitor